BiotechTube

ZN-d5

Phase 1Completed
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Acute Myeloid Leukemia

Conditions

Acute Myeloid Leukemia, Non Hodgkin Lymphoma

Trial Timeline

Oct 13, 2020 → Dec 12, 2023

NCT ID
NCT04500587

About ZN-d5

ZN-d5 is a phase 1 stage product being developed by Zentalis Pharmaceuticals for Acute Myeloid Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT04500587. Target conditions include Acute Myeloid Leukemia, Non Hodgkin Lymphoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (3)

NCT IDPhaseStatus
NCT05199337Phase 1/2Completed
NCT04854174Phase 1Completed
NCT04500587Phase 1Completed

Competing Products

20 competing products in Acute Myeloid Leukemia

See all competitors
ProductCompanyStageHype Score
AFM28AffimedPhase 1
25
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + PlaceboTrevenaPhase 1
25
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
44
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
Oliceridine + Placebo + MorphineTrevenaPhase 3
69
TRV130TrevenaPhase 3
69
TRV130 + Morphine + PlaceboTrevenaPhase 2
44
Venetoclax Combining Chidamide and Azacitidine (VCA) regimen followed by dicitabine combined with liposome mitoxantrone, cytarabine, and G-CSF (D-MAG) regimenCSPC Pharmaceutical Group LimitedPhase 2
51
Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T CellsCSPC Pharmaceutical Group LimitedPhase 2
51
SPT-07A injectionSinopharmPhase 3
76
PRGN-3006 T CellsPrecigenPhase 1
28
BisantreneRace OncologyPhase 2
44
Bisantrene Dihydrochloride (high dose) + Bisantrene Dihydrochloride (low dose) + Cytarabine Hydrochloride + Decitabine and cedazuridineRace OncologyPhase 1
25
Bisantrene + Fludarabine + ClofarabineRace OncologyPhase 2
44
ZN-d5 ZN-c3 + ZN-c3Zentalis PharmaceuticalsPhase 1/2
33
VIP943 (QW) + VIP943 (BIW)Vincerx PharmaPhase 1
25
LY2523355Eli LillyPhase 1
33
TomivosertibeFFECTOR TherapeuticsPhase 1
25
gemtuzumab ozogamycinChugai PharmaceuticalPhase 3
77
YH14659 + clopidogrel & aspirinYuhanPhase 1
33

Other Products from Zentalis Pharmaceuticals

Zentalis + GemzarPhase 2
44
AzenosertibPhase 2
44
azenosertibPhase 2
44
Azenosertib + Carboplatin + PembrolizumabPhase 1/2
33
ZN-d5 ZN-c3 + ZN-c3Phase 1/2
33